

CENTRAL NEW JERSEY MULTIPLE MYELOMA SUPPORT GROUP

AUGUST 6, 2025 VIRTUAL MEETING RECAP

The Central New Jersey Multiple Myeloma Support Group met virtually on August 6, 2025 and there were 28 members in attendance.

IMPORTANT ANNOUNCEMENT: Due to the support group members attending the Somerset Patriots Ballgame on September 3, the September support group meeting will be rescheduled for Wednesday, September 10, 2025.

Guest Speaker: Michael Riotto, Grassroots Advocacy, International Myeloma Foundation

Along with the work that Michael does for the IMF and its Advocacy program, he is a 14 year MM survivor and the Co-Leader of the Philadelphia MM Support Group.

You can read about Michael's MM journey here at "BMT Infonet"

<https://bmt-dev.themis.cividesk.net/story/multiple-myeloma-michaels-story>

Below are some bullet points Michael talked about that the Advocacy Team at the IMF have been involved in and are presently working on...

- No Surprises Act – “The No Surprises Act (NSA) is a federal law that went into effect on January 1, 2022, designed to protect

consumers from unexpected medical bills, particularly those arising from out-of-network care in emergency situations or at in-network facilities. The law limits the amount patients are required to pay for out-of-network services to their in-network cost-sharing amount (copay, coinsurance, or deductible).”

- Safe Step Act – “The Step Therapy Protocol Act, also known as the Safe Step Act, aims to reform step therapy protocols in health insurance plans. Step therapy, also called “fail first,” requires patients to try and fail on less expensive medications before their insurer will cover a prescribed, potentially more effective treatment. The Safe Step Act seeks to ensure patients have timely access to the most appropriate treatments by establishing clear exceptions and expedited review processes for step therapy protocols.” Presently was introduced to the Senate in 2023.
- The PBM Reform Act – “The PBM Reform Act is a proposed piece of legislation aimed at regulating pharmacy benefit managers (PBMs) and addressing concerns about rising drug costs and PBM practices. It has bipartisan support and seeks to curb practices like spread pricing, where PBMs charge insurance plans more for drugs than they reimburse pharmacies. The act also aims to increase transparency and accountability in the PBM industry.” Presently was introduced to the Senate in 2023.
- Telehealth Modernization Act of 2024 – “This bill will ensure permanent access to telehealth services for Medicare beneficiaries and extends these flexibilities to federally qualified health centers and rural health clinics. By increasing

telehealth access and providing certainty about its future, more patients, particularly seniors and those in rural areas, will be able to access timely, high-quality care.” Introduced to the House of Representatives 2024.

- Oral Parity – “Oral parity laws, in the context of cancer treatment, mandate that insurance companies provide the same level of coverage for oral chemotherapy drugs as they do for intravenous (IV) chemotherapy drugs. This means that out-of-pocket costs, such as co-pays and deductibles, should be equivalent for both types of treatment. The goal is to ensure that patients have equal access to all cancer treatment options, regardless of whether they are administered orally or intravenously.” Forty-three states and the District of Columbia have enacted this law. On the Federal level, the Cancer Drug Parity Act of 2023, has been referred to the Committee on Health, Education, Labor, and Pensions, by the Senate.
- HELP Co-pays Act – “The Help Ensure Lower Patient Copays Act (HELP Copays Act) is a bipartisan bill aimed at ensuring that payments made by or on behalf of patients, including copay assistance, are applied towards their health insurance cost-sharing requirements (deductibles and out-of-pocket maximums). This act would prevent "copay accumulator programs" which prevent copay assistance from being counted towards these limits.” Currently it has been referred to the Committee on Health, Education, Labor, and Pensions by the Senate.
- Inflation Reduction Act – “The Inflation Reduction Act (IRA) of 2022 is a United States federal law focused on reducing the

federal budget deficit, lowering prescription drug prices, and investing in domestic energy production and clean energy initiatives.”

The Advocacy Team is also involved in advancing Myeloma Research through Federal funding, and Clinical Trial Access to all MM Patients.

You can visit the IMF Advocacy page here

<https://www.myeloma.org/take-action/advocacy>

Sign up for Advocacy alerts and campaign notices here

<https://secure.myeloma.org/page/41507/subscribe/1>

Read how to become and Advocate for the IMF here

<https://www.myeloma.org/become-advocate>

Read about the IMF’s role in Advocacy here

<https://www.myeloma.org/advocacy-101>

Myeloma News:

- **FDA Eliminates Risk Evaluation and Mitigation Strategies (REMS) for Autologous Chimeric Antigen Receptor (CAR) T cell Immunotherapies**
 - <https://www.fda.gov/vaccines-blood-biologics/safety-availability-biologics/fda-eliminates-risk-evaluation-and-mitigation-strategies-rems-autologous-chimeric-antigen-receptor>
- **FDA grants accelerated approval to linvoseltamab-gcpt for relapsed or refractory multiple myeloma**

- <https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-linvoseltamab-gcpt-relapsed-or-refractory-multiple-myeloma>
- **U.S. FDA Extends Review Period for Blenrep (belantamab mafodotin) for Relapsed or Refractory Myeloma**
- **FDA Grants Accelerated Approval to Lynozyfic™ (linvoseltamab-gcpt) for Relapsed/Refractory Multiple Myeloma**
- **FDA Eliminates REMS Program for Certain Autologous CAR T-cell Therapies**
- **FDA Removes Required REMS Program for Approval of Abecma (ide-cel) and for Breyanzi (liso-cel)**
 - <https://www.myeloma.org/>
- **FDA Grants Orphan Drug Status to SAR446523 for Relapsed Myeloma**
- **FDA Votes Against Proposed Blenrep Treatment Combo's for Multiple Myeloma**
- **FDA Grants Accelerated Approval of Lynozyfic for Multiple Myeloma**
 - <https://www.curetoday.com/tumor/myeloma>
- **FDA ODAC Votes Belantamab Mafodotin Risks Outweigh Benefits in Myeloma**
 - <https://www.targetedonc.com/clinical/multiple-myeloma-rc>
- **LLS Unveils Name Change to Reach All Blood Cancer Patients**
 - <https://www.lls.org/news/lls-unveils-name-change-reach-all-blood-cancer-patients>

- **FDA Approves New Dosing Schedule for Elrexfio in Rel/Ref Multiple Myeloma**
 - <https://www.cancertherapyadvisor.com/news/fda-approves-new-dosing-schedule-for-elrexfio-in-rel-ref-multiple-myeloma/>
- **Dana-Farber Cancer Institute Unveils Groundbreaking Blood Test for Multiple Myeloma**
 - <https://www.dana-farber.org/newsroom/news-releases/2025/dana-farber-cancer-institute-unveils-groundbreaking-blood-test-for-multiple-myeloma>
- International Myeloma Foundation
 - <https://www.myeloma.org/>
- **Supplemental Myeloma Support Groups**
 - **Multiple Myeloma Care Partner Support Group (virtual)**
 - **September 11 @ 7:00 pm ET**
 - **Las Voces de Mieloma**
 - **August 19 @ 1:00 pm ET**
 - **Living Solo and Strong with Myeloma**
 - **September 9 @ 6:00 pm ET**
 - **Living Well with High Risk Multiple Myeloma**
 - **Meets 3rd Thursday of each month, alternating daytime/evening hours. Odd months, 12:00 pm ET, even months 7:00 pm ET. Next meeting September 18 @ 12:00 pm ET**
 - **MGUS 4 US**
 - **Please email Emily Gordon at erg2172@cumc.columbia.edu if you have questions or for meeting information**
 - **Smolder Bolder**

- **September 8 @ 7:30-9:30 pm ET**
- **Strength Through Inspiration: A Virtual Support Group for Multiple Myeloma Patients & Caregivers who have Young Children (every other month)**
 - **September 9 @ 8:00-9:00 pm ET**
- **The Veterans with Myeloma Special Interest Group (Virtual)**
 - **Meets the 4th Wednesday of the month. For more information or to sign up for group emails please reach out to veterans@IMFsupport.org or visit our webpage at veterans.support.myeloma.org.**
 - **September 17 @ 5:00 pm EDT**

Support Group News:

- **Miracles for Myeloma**
 - At our last M4M committee meeting, Ron Pask provided us with the following numbers...
 - 18 Teams have signed up
 - 168 participants have signed up
 - 25 Remembrance Path Placards have been purchased
 - Over \$40K has been raised so far!!
 - The Central NJ Support Group Team
 - 17 Team Members
 - Over \$3600 raised so far!!
 - Date of race...September 13, 2025 (a little over 4 weeks to go!!)
 - Place...Oak Ridge Park, Clark NJ

- Be part of the Miracle! Join the Central NJ Support Group Team, create your own team, join someone else's team from the group, participate on your own either in person or virtually, purchase a Remembrance Path Placard to honor or remember someone who has/had Myeloma (you can view the Placards online as well as on race day), or you can donate
 - <https://fundraise.myeloma.org/event/miracles-for-myeloma-virtual-in-person-5k-run-walk-clark-nj/e640168>
- Another Book Recommendation
 - An Exercise in Uncertainty: A Memoir of Illness and Hope by Jonathan Gluck
 - “In this thought-provoking memoir, an award-winning journalist explores the chaos, doubt, and search for meaning that come with staying one step ahead of cancer for decades.” “At age thirty-eight, Jonathan Gluck, a new father with a promising journalism career, was shocked to learn he had multiple myeloma, a rare, incurable blood cancer. He was told he had eighteen months to live. That was more than twenty years ago.”

CENTRAL NEW JERSEY MULTIPLE MYELOMA SUPPORT GROUP

VIRTUAL MEETING RECAP FOR AUGUST 6, 2025

INFORMATIONAL MYELOMA LINKS

FDA

- **FDA Eliminates Risk Evaluation and Mitigation Strategies (REMS) for Autologous Chimeric Antigen Receptor (CAR) T cell Immunotherapies**
 - <https://www.fda.gov/vaccines-blood-biologics/safety-availability-biologics/fda-eliminates-risk-evaluation-and-mitigation-strategies-rems-autologous-chimeric-antigen-receptor>
- **FDA grants accelerated approval to linvoseltamab-gcpt for relapsed or refractory multiple myeloma**
 - <https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-livoseltamab-gcpt-relapsed-or-refractory-multiple-myeloma>

International Myeloma Foundation

<https://www.myeloma.org/>

- Key Takeaways from the Top Myeloma Research Presented at ASCO, EHA, & IMWG 2025 Webinar: The Patient Perspective (Part 1 of 2)
 - Smoldering Myeloma
 - Frontline Therapy
 - Early Relapse
- Learn How You Can Support the IMF's 2025 Iceland Cycling Expedition

- Watch the Replay of the IMF Virtual Myeloma Community Workshop (MCW): What's Next? – Managing Myeloma at Relapse
- **Supplemental Myeloma Support Groups**
 - **Multiple Myeloma Care Partner Support Group (virtual)**
 - **September 11 @ 7:00 pm ET**
 - **Las Voces de Mieloma**
 - **August 19 @ 1:00 pm ET**
 - **Living Solo and Strong with Myeloma**
 - **September 9 @ 6:00 pm ET**
 - **Living Well with High Risk Multiple Myeloma**
 - **Meets 3rd Thursday of each month, alternating daytime/evening hours. Odd months, 12:00 pm ET, even months 7:00 pm ET. Next meeting September 18 @ 12:00 pm ET**
 - **MGUS 4 US**
 - **Please email Emily Gordon at erg2172@cumc.columbia.edu if you have questions or for meeting information**
 - **Smolder Bolder**
 - **September 8 @ 7:30-9:30 pm ET**
 - **Strength Through Inspiration: A Virtual Support Group for Multiple Myeloma Patients & Caregivers who have Young Children (every other month)**
 - **September 9 @ 8:00-9:00 pm ET**
 - **The Veterans with Myeloma Special Interest Group (Virtual)**
 - **Meets the 4th Wednesday of the month. For more information or to sign up for group emails please**

reach out to veterans@IMFsupport.org or visit our webpage at veterans.support.myeloma.org.

- **September 17 @ 5:00 pm EDT**

News

- **U.S. FDA Extends Review Period for Blenrep (belantamab mafodotin) for Relapsed or Refractory Myeloma**
- The International Myeloma Foundation Brings the Patient Voice and Science to FDA-ODAC Meeting; Advocates for BLENREP® (belantamab mafodotin) in Triplet Drug Combinations for the Treatment of Relapsed/Refractory Myeloma
- The International Myeloma Foundation's Brian D. Novis Research Grants: Celebrating 30 Years of Paving the Way for Transformative Breakthroughs in Myeloma Research
- European Hematology Association (EHA) and the European Myeloma Network (EMN) Include Pepaxti in New Clinical Practice Guidelines for Relapsed/Refractory Multiple Myeloma
- **FDA Grants Accelerated Approval to Lynozyfic™ (linvoseltamab-gcpt) for Relapsed/Refractory Multiple Myeloma**
- **FDA Eliminates REMS Program for Certain Autologous CAR T-cell Therapies**
- **FDA Removes Required REMS Program for Approval of Abecma (ide-cel) and for Breyanzi (liso-cel)**
- July 2025 – Myeloma News from the Journals

Events

- Blogs
 - June and July 2025: What's New in Myeloma?

- ASCO, EHA, and IMWG: Three-Fold Impact for Myeloma Researchers and the Patient Community
- Access to a Long-Term Myeloma Specialist is Integral to Your Care
- Top Takeaways from the 2025 IMWG Conference Series: Making Sense of Treatment (Part 1 of 2)
- Top Takeaways from the 2025 IMWG Conference Series: Making Sense of Treatment (Part 2 of 2)
- IMF Videos
 - ASCO/EHA
 - Early Relapsed Multiple Myeloma: What's Changing in 2025 | Research Breakthroughs from ASCO & EHA
 - Key Abstracts Presented at ASCO and EHA 2025
 - **Plus other videos from ASCO and EHA**
 - ASH
 - Ask Dr. Durie
 - Black Swan Research Initiative
 - Community Workshops
 - IMF Virtual Myeloma Community Workshop (MCW): What's Next? – Managing Myeloma at Relapse (Replay with slides)
 - Emerging Therapies
 - Relapsed Multiple Myeloma in 2025: What Every Patient Needs to Know
 - Top 10 Myeloma Breakthroughs from ASCO & EHA: Frontline Therapy, Early & Late Relapse, and CAR T-cell Insights
 - Multiple Myeloma Q&A: Why Diagnosis Can Take 12+ Months, MGUS, Costs & FDA News

- Palliative Care in Multiple Myeloma: What It Really Means for Patients and Families
 - Facebook Live
 - Multiple Myeloma Clinical Trials Explained & QA | Expert Advice & Real Patient Stories (Prior event...transcript available)
 - Health Equity
 - IMF History
 - IMWG
 - Inspirational
 - Living Well With Myeloma
 - Myeloma Made Simple
 - Infection Management for Bispecific Antibodies: A Patient's Guide
 - Why 4 Drugs Work Better in Myeloma: Quadruplet Therapy Explained | Myeloma Made Simple
 - Talquetamab Side Effects: Managing Taste Loss, Hair & Nail Changes in Myeloma
 - Myeloma University
 - NLB Webcasts
 - Patient and Family Webinars
 - Regional Community Workshops
 - Treatments
 - Emerging Therapies
 - Newly Diagnosed Multiple Myeloma: What's Changing in 2025? | ASCO & EHA
 - Relapsed Multiple Myeloma in 2025: What Every Patient Needs to Know
- What is Multiple Myeloma
 - Newly Diagnosed

- Tests and Staging
 - Treatment
- Publications and Broadcasts
 - IMF Publications
 - IMF Broadcasts
 - Healthcare Professional Resource
- Resources and Support
 - IMF Support Network
 - Diversity, Equity, Inclusion
 - **External Resources**
 - **Drug Reimbursement Information and Assistance**
 - **Financial Assistance**
 - **Government Assistance**
 - **Guidance and Support**
 - **Housing and Travel Assistance**
 - **International Support**
 - **Legal Assistance**
 - **Pain Management**
 - **Transplant Resources**
 - **Other Cancer Resources**
- Veterans Against Myeloma
 - <https://www.myeloma.org/veterans-against-myeloma>
- M-Power
- **IMF's Infoline**
 - <https://www.myeloma.org/infoline>
 - **800-452 CURE (2873)**
 - **Email: infoline@myeloma.org**
- IMF Medical Research
 - Black Swan Research Initiative

- International Myeloma Working Group
- Asian Myeloma Network
- Road to the Cure
- Nurse Leadership Board
 - Nurse Leadership Board Members
 - Nurse Leadership Board Publications
 - Nursing Resources

Multiple Myeloma Research Foundation

<https://themmrf.org/>

- Blogs
 - Multiple Myeloma Highlights From the 2025 ASCO and EHA Annual Meetings
 - ODAC Reviews Darzalex Faspro® for Patients with High-Risk Smoldering Myeloma
 - Miami Myeloma MRD 2025 Meeting
 - The State of Blenrep: What Patients Should Know
 - MMRF at ASCO 2025: Day 1 – What Patients Should Know
 - MMRF at ASCO 2025: Day 2 – What Patients Should Know
 - FDA Removes REMS Requirements for CAR T
- Press Release
- Navigating Diagnosis & Treatment
- Understanding Multiple Myeloma
- Navigating Diagnosis & Treatment
- Finding Support
- Patient Navigation Center

- Myeloma Mentors
- Education Resource Hub
 - Myeloma Matters Podcast
 - Events
 - **Patient Webinar**
 - **Understanding Bispecifics**
 - **May 28, 2025**
 - **12:00 pm EDT**
 - **No additional information available yet**
 - MMRF Patient Toolkit
- Resources on Demand
- Video
 - FAQs on Myeloma Updates from ASCO and EHA 2025
 - Multiple Myeloma Community Connect
 - Houston Community Connect
 - Myeloma Updates from ASCO & EHA 2025: What You Need to Know
- Finding a Cure
- Patient Navigation Center
 - **Monday–Friday, 9 AM–7 PM ET 1-888-841-MMRF (6673)**
 - Information and Resources
 - Perspective on Treatments
 - Support
 - Get on the Right Path for You
 - Right Team
 - Right Tests
 - Right Treatment

- Meet the Patient Navigators
- Connect with a Myeloma Mentor

Myeloma Matters – MMRF Podcast

<https://www.youtube.com/playlist?list=PL6YqSpftWXYZht7lBSsLFkyvKsWAZSGq4>

- Great Topics!

HeathTree Foundation for Multiple Myeloma

<https://healthtree.org/>

- Education
 - News Articles
 - Conference Updates
- Educational Resources
 - University
 - Patient Guides
 - Expert Webinars
 - Many upcoming interesting webinars
 - Learn from Specialists
 - Find a Specialist
 - Podcasts
 - HealthTree Roundtables
 - Additional Resources
 - Myeloma 101
 - Newly Diagnosed Guide
 - Financial Resources
 - Medications
 - Understanding Labs

- Community
 - Join the Conversation
 - Connect
 - Join a social platform specifically for Multiple Myeloma
 - Patient-to-Patient Connections
 - Coach
 - Find a personal coach to help navigate your Myeloma
 - Moves
 - Tackle challenges and crush your fitness goals together
 - Community Events
 - All Events
 - Join Educational Groups
 - Attend Topic Based Events to Further Your Cancer Education
 - Community Support Groups
 - Black and Hispanic Support
 - Black Myeloma Health
 - Resources in Spanish
- Cure Hub
 - Join Cure Hub
 - Track Your Disease
 - Connect Medical Records
 - See Tracked Labs
 - Record Side Effects
 - Find the Best Treatments
 - Treatment Options
 - Clinical Trial Finder

- Twin Machine
- Find Support
 - Find Side Effect Solutions
 - My Journal
 - Journal Your Multiple Myeloma Story
 - Register for Cure Tour

HealthTree University – YouTube

<https://www.youtube.com/c/HealthTreeUniversity>

- First-In-Human Study for Novel Trispecific Antibody
 - <https://www.youtube.com/watch?v=40nbk9fd3MQ>
- Updates on Belantamab Mafadotin | Paul Richardson, MD
 - <https://www.youtube.com/watch?v=4nQzBDeBnlc>
- How Frequently Are Bone Marrow Biopsies Needed? A Patient’s Guide-Dr. Richter
 - <https://www.youtube.com/watch?v=LdbtHC-CszM>
- Boosting the Power of CAR-T and Bispecifics in Myeloma | What’s Being Done to Improve Response?
 - <https://www.youtube.com/watch?v=1hGGVjOnAUc>
- Starting Myeloma Treatment – A series of videos for the newly diagnosed patient
 - <https://www.youtube.com/playlist?list=PLJlQreXXYN7K4JgoUjA5LG9x-ofx1uW3Y>

SparkCures

<https://sparkcures.com/>

- Myeloma Support...Personalized.

- “Whether it's clinical trials, treatments or finding a myeloma specialist, we help you understand your myeloma options”
- 888-828-2206
- Now featuring trial options for MDS (Myelodysplastic Syndromes) and NTRK Gene Fusion Cancers

Myeloma Central

<https://www.myelomacentral.com/>

- Standing in the Gaap
 - Resources for African Americans
- Multiple Myeloma Resources for Nurses

Cure

<https://www.curetoday.com/tumor/myeloma>

- Latest News
 - **FDA Grants Orphan Drug Status to SAR446523 for Relapsed Myeloma**
 - **FDA Votes Against Proposed Blenrep Treatment Combo’s for Multiple Myeloma**
 - **FDA Grants Accelerated Approval of Lynozyfic for Multiple Myeloma**

Video Series

- Video Interviews
- Podcasts
- Other News

Cure – Cancer Horizons

<https://www.curetoday.com/cancer-horizons/myeloma>

CureTalks

<https://www.youtube.com/@CureTalks/search?query=myeloma>

OncLive/OncLive Videos

<https://www.onclive.com/>

- Search “Myeloma”
 - Elranatamab Triplet Yields Nearly 100% ORR in Newly Diagnosed Multiple Myeloma
 - <https://www.onclive.com/view/elranatamab-triplet-yields-nearly-100-orr-in-newly-diagnosed-multiple-myeloma>

Many other great articles and videos!

Multiple Myeloma Hub

<https://multiplemyelomahub.com/>

- Phase II GMMG-CONCEPT trial: Final analysis of Isa-KRd in patients with HR NDMM
 - <https://multiplemyelomahub.com/medical-information/phase-ii-gmmg-concept-trial-final-analysis-of-isa-krd-in-patients-with-hr-ndmm>

- How are BCMA-directed bispecific antibodies currently utilized in real-world practice for MM?
 - <https://multiplemyelomahub.com/medical-information/how-are-bcma-directed-bispecific-antibodies-currently-utilized-in-real-world-practice-for-mm>
- News
 - Management of ocular toxicities associated with belantamab mafodotin in RRMM: Latin American expert panel recommendations
 - **FDA grants orphan drug designation to SAR446523 for the treatment of RRMM**
 - Phase II GMMG-CONCEPT trial: Final analysis of Isa-KRd in patients with HR NDMM
 - Visual abstract | MonumenTAL-1: Long-term follow-up of talquetamab for the treatment of RRMM
- Recent Content
 - First-in-human trial of JNJ-5322 in patients with RRMM: Preliminary phase I results
- Most Read
- Congresses
- Newly Diagnosed Myeloma
- 2024 Symposium

Patient Power

<https://www.patientpower.info/multiple-myeloma>

American Society of Hematology (ASH)

<https://www.hematology.org/>

ASH Clinical News

- Real-World Venetoclax Combinations for MM Show Evidence of Efficacy in Patients Harboring t(11;14)
 - <https://ashpublications.org/ashclinicalnews/news/8624/Real-World-Venetoclax-Combinations-for-MM-Show>
- Daratumumab Shows Clinical Activity, No New Safety Concerns With Extended Use in Intermediate/High-Risk Smoldering MM
 - <https://ashpublications.org/ashclinicalnews/news/8622/Daratumumab-Shows-Clinical-Activity-No-New-Safety?searchresult=1>

The ASCO Post

<https://ascopost.com/search-results/?q=myeloma>

- Case 1: Role of ASCT in the Era of Quadruplet Induction and T-Cell–Redirected Therapies
- Case 2: Role of T-Cell–Redirected Therapies in Elderly Patients With Relapsed/Refractory Multiple Myeloma
- Case 3: Optimal Sequencing of T-Cell–Redirected Therapies
- Novel Single-Cell Sequencing Blood Test for Multiple Myeloma
- Outcomes Associated With COVID-19 Infection in Patients With Cancer

- Evidence of Potential Cure With Single CAR T-Cell Infusion for Some Patients With Multiple Myeloma
- DREAMM-7 Analysis Compares Survival Outcomes Between Triplet Regimens for Relapsed or Refractory Multiple Myeloma
- Teclistamab for High-Risk, Heavily Pretreated Multiple Myeloma: Real-World Data

Blood

<https://ashpublications.org/blood>

- A natural head start to MRD negativity in multiple myeloma
 - <https://ashpublications.org/blood/article/145/25/2936/537727/A-natural-head-start-to-MRD-negativity-in-multiple>
- When the silence speaks: T-cell dysfunction in myeloma
 - <https://ashpublications.org/blood/article/145/26/3064/537863/When-the-silence-speaks-T-cell-dysfunction-in>
- More than myeloma: the trouble with “normal” plasma cells
 - <https://ashpublications.org/blood/article/145/26/3066/537859/More-than-myeloma-the-trouble-with-normal-plasma>
- Are we ready for an MRD-driven approach in multiple myeloma?
 - <https://ashpublications.org/blood/article/146/1/2/537974/Are-we-ready-for-an-MRD-driven-approach-in>
- Real-world data provide a CARbon copy for ide-cel
 - <https://ashpublications.org/blood/article/146/2/131/538054/Real-world-data-provide-a-CARbon-copy-for-ide-cel>
- Silence of the myeloma clones: GPRC5D epigenetic regulation

- <https://ashpublications.org/blood/article/146/2/133/538056/Silence-of-the-myeloma-clones-GPRC5D-epigenetic>
- Time-tested safety: FCARH143's 5-year myeloma journey
 - <https://ashpublications.org/blood/article/146/5/519/546331/Time-tested-safety-FCARH143-s-5-year-myeloma>
- Myeloma: a sky full of MRD stars
 - <https://ashpublications.org/blood/article/146/6/649/546426/Myeloma-a-sky-full-of-MRD-stars>
- Sustained MRD negativity: robust, not all-powerful
 - <https://ashpublications.org/blood/article/146/6/652/546425/Sustained-MRD-negativity-robust-not-all-powerful>
- Isatuximab, carfilzomib, lenalidomide, and dexamethasone induction in newly diagnosed myeloma: analysis of the MIDAS trial
 - <https://ashpublications.org/blood/article-abstract/146/1/52/535235/Isatuximab-carfilzomib-lenalidomide-and>
- Large-scale dependency and drug screens to characterize the therapeutic vulnerabilities of multiple myeloma with 1q+
 - <https://ashpublications.org/blood/article-abstract/146/1/89/536006/Large-scale-dependency-and-drug-screens-to?redirectedFrom=fulltext>
- IVIG prophylaxis should be initiated following bispecific antibody therapy in multiple myeloma regardless of IgG levels
 - <https://ashpublications.org/bloodadvances/article/doi/10.1182/bloodadvances.2025016490/546292/IVIG-prophylaxis-should-be-initiated-following>
- Cytolytic helper T cells: a new addition to myeloma immunity
 - <https://ashpublications.org/blood/article/146/4/402/546215/Cytolytic-helper-T-cells-a-new-addition-to-myeloma>

- Sequential Targeting in Multiple Myeloma: Talquetamab, a GPRC5D bispecific antibody, as a Bridge to BCMA CAR-T cell therapy
 - <https://ashpublications.org/blood/article-abstract/doi/10.1182/blood.2025029773/546455/Sequential-Targeting-in-Multiple-Myeloma>

Blood Cancer Talks - Podcast

<https://podcasts.apple.com/us/podcast/blood-cancer-talks/id1633724992>

- Episode 62. Unpacking MIDAS Trial in Myeloma with Dr. Meera Mohan

Healio

<https://www.healio.com/search?q=myeloma&sort=relevancy>

The Patient Story

<https://thepatientstory.com/patient-stories/multiple-myeloma/>

Targeted Oncology

<https://www.targetedonc.com/clinical/multiple-myeloma-rc>

- Latest News
 - Real-World Evidence Reveals CAR T Sequencing Approach in Myeloma

- Novel CAR T-Cell Therapy FCARH143 Delivers High Responses and Survival in Relapsed/Refractory Multiple Myeloma
- Measuring Sustained MRD Provides Path to Tailoring Myeloma Therapy
- Novel GPRC5D mAB Receives FDA Orphan Drug Designation in R/R Myeloma
- Video Series
- Video Interviews
- Podcasts
- More News
 - **FDA ODAC Votes Belantamab Mafodotin Risks Outweigh Benefits in Myeloma**
 - Prior BCMA-Directed Therapy Linked to Diminished Teclistamab Efficacy in Relapsed/Refractory Multiple Myeloma
 - Distinguishing Early and Late-Presenting CAR T Toxicities
 - Across Cancer Types, Trispecific Antibodies Show Promise in Early Result
 - Plus many more articles

Cancernetwork

<https://www.cancernetwork.com/>

- Many great articles!
- Search “Myeloma”

Patient Empowerment Network

<https://powerfulpatients.org/help-by-cancer-diagnosis/multiple-myeloma/>

Managing Myeloma

<https://managingmyeloma.com/>

- Many great articles!

Smart Patients

<https://www.smartpatients.com/>

Blood Cancers Today

<https://www.bloodcancerstoday.com/page/myeloma>

- Daratumumab Outperforms Observation in High-Risk Smoldering Multiple Myeloma
 - <https://www.bloodcancerstoday.com/post/daratumumab-outperforms-observation-in-high-risk-smoldering-multiple-myeloma>
- Cilta-Cel Delivers Sustained Survival Benefits Across Genetic Risk Profiles in MM
 - <https://www.bloodcancerstoday.com/post/cilta-cel-delivers-sustained-survival-benefits-across-genetic-risk-profiles-in-mm>
- Joshua Richter, MD, Talks Results From LINKER-MM1 Study (video)
 - <https://www.bloodcancerstoday.com/post/joshua-richter-md-talks-results-from-linker-mm1-study>

Many other great articles

HemOnc Pulse (Podcast)

- From Trials to Practice: What's New and What's Next for Myeloma
 - <https://www.bloodcancerstoday.com/page/the-hemonc-pulse>

Blood & Marrow Transplant Information Network

<https://bmtinfonet.org/>

- “Blood & Marrow Transplant Information Network (BMT InfoNet) is not-for-profit 501 (c) 3 organization dedicated to providing transplant and CAR T-cell therapy recipients and their loved ones with emotional support and high quality, easy-to-understand information about bone marrow, peripheral blood stem cell and cord blood transplant, and CAR T-cell therapy.”

Leukemia/Lymphoma Society

<https://www.lls.org/>

- **LLS Unveils Name Change to Reach All Blood Cancer Patients**
 - <https://www.lls.org/news/lls-unveils-name-change-reach-all-blood-cancer-patients>
- FDA Approves New Immune-based Therapy for Multiple Myeloma
- The Bloodline with LLS

- <https://thebloodline.org/>
- Podcast
 - Sound the Alarm: Firefighter Health, Cancer Risk, and Moving Forward
- Video Podcast

New Weekly Online Chat:

- **Veterans Living with Blood Cancer**
- **Every Tuesday Evening @ 8:00-10:00pm EDT**
- **Online Chat for Caregivers:**
 - **Every Monday Evening @ 8:00-10:00 pm EDT**
- **Online Chat Living with Myeloma:**
 - **Every Monday Evening @ 8:00-10:00 pm EDT**

*****Visit <https://www.lls.org/support-resources/online-chats>**

to register for the Chat you would like to attend***

Download or order our new materials for free

- **Mental Health**
- **Hospice Care**
- **Blood and Marrow Stem Cell Transplantation**
- **Podcasts**
- **LLS Community**
- **Peer-to-peer support**
- **On-Line Chat**
- **Speak To An Information Specialist**
- **Monday - Friday 9 am to 9 pm ET**

- **Call: (800) 955-4572**
- **Financial Support**
- **Co-pay Assistance Program**

Oncology Nursing News

<https://www.oncnursingnews.com/clinical/multiple-myeloma>

- Latest News
- Videos
- Video Interviews
- Podcasts
- More News

Nature

<https://www.nature.com/search?q=myeloma&journal=>

- Fractures incidence and its association on mortality in multiple myeloma patients: a nationwide cohort study (CAREMM-2105 study)
- High glutamate levels in the bone marrow of multiple myeloma patients promote osteoclast formation: a novel target for osteolytic bone disease
- Outcomes following different upfront stem cell transplantation strategies for multiple myeloma: a statistical perspective on behalf of the Chronic Malignancies Working Party of the EBMT
- The bone marrow immune ecosystem shapes daratumumab acquired resistance in plasma cell myeloma

- Engineering anti-BCMA CAR T cells for enhancing myeloma killing efficacy via apoptosis regulation
- Value of serum-free light chain measurements in response and progression assessment in multiple myeloma with monoclonal protein measurable by electrophoresis
- AI-based body composition analysis of CT data has the potential to predict disease course in patients with multiple myeloma
- Activity of CAR-T cells and bispecific antibodies in multiple myeloma with extramedullary involvement
- EHA–EMN Evidence-Based Guidelines for diagnosis, treatment, and follow-up of patients with multiple myeloma
 - <https://www.nature.com/articles/s41571-025-01041-x#Abs1>

VJHemonc (Video Journal of Oncology)

<https://www.vjhemonc.com/subject/multiple-myeloma/>

- The Multiple Myeloma Channel
 - Latest Videos
 - Myeloma Sessions
 - Conferences
 - Topics
 - Podcasts
 - Features
 - VJ today

American Journal of Managed Care

https://www.ajmc.com/search?ajmc_sanity_data%5Bquery%5D=myeloma

- Linvoseltamab Offers Hope for Patients With Refractory Multiple Myeloma: Sundar Jagannath (video)
 - <https://www.ajmc.com/view/linvoseltamab-offers-hope-for-patients-with-refractory-multiple-myeloma-sundar-jagannath-mbbs>
- Safety Should Always Be a Priority With Car T for Multiple Myeloma: Surbhi Sidana, MD, MBBS
- PET/CT Helps Predict Relapse in Patients With Myeloma Undergoing CAR T-Cell Therapy
- Advancing First-Line Therapy for Multiple Myeloma: Updates From IsKia and IMROZ Trials
- Plus many more informative articles

Triage Cancer

<https://tragecancer.org/>

- Events
- Resources
- Materials
- Support

Clinical Hematology International

- Prolonged Cytopenia with CAR-T Cell Therapy and Management Recommendations

- <https://chi.scholasticahq.com/article/126463-prolonged-cytopenia-with-car-t-cell-therapy-and-management-recommendations>

The Lancet

- Venetoclax or placebo in combination with bortezomib and dexamethasone in relapsed or refractory multiple myeloma (BELLINI): final overall survival results from a randomised, phase 3 study
 - [https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026\(25\)00139-5/abstract](https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(25)00139-5/abstract)
- In-vivo B-cell maturation antigen CAR T-cell therapy for relapsed or refractory multiple myeloma
 - <https://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2825%2901030-X/fulltext>

SOHO (Society of Hematology Oncology) Insider Podcast

- The journey of belantamab mafodotin in multiple myeloma
 - With Dr. Usmani and Dr. Lonial
 - <https://sohoinsider.com/soho-insider-podcast/belantamab-mafodotin-myeloma-dreamm-trials/>

Journal of Clinical Oncology

- Isatuximab Subcutaneous by On-Body Injector Versus Isatuximab Intravenous Plus Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Phase III IRAKLIA Study

- <https://ascopubs.org/doi/full/10.1200/JCO-25-00744>
- Long-Term (≥5-Year) Remission and Survival After Treatment With Ciltacabtagene Autoleucel in CARTITUDE-1 Patients With Relapsed/Refractory Multiple Myeloma
 - <https://ascopubs.org/doi/10.1200/JCO-25-00760>

EurekAlert (AAAS – American Association for the Advancement of Science)

- Real-world data shows teclistamab can benefit many multiple myeloma patients who would have been ineligible for pivotal trial
 - <https://www.eurekalert.org/news-releases/1090003>

Inside Precision Medicine

- New Imaging Method Tracks Multiple Myeloma Treatment Success
 - <https://www.insideprecisionmedicine.com/topics/oncology/new-imaging-method-tracks-multiple-myeloma-treatment-success/>

Wiley Online Library

- Maintenance Therapy in the Era of Quadruplets for Multiple Myeloma: When, What, and for How Long?
 - <https://onlinelibrary.wiley.com/doi/10.1002/ajh.70002>
- Real-World Treatment Patterns and Outcomes in Patients With Relapsed/Refractory Multiple Myeloma and 1–3 Prior Lines of Therapy: Optum Database
 - <https://onlinelibrary.wiley.com/doi/10.1002/cam4.71093>

- A German multicenter real-world analysis of talquetamab in 138 patients with relapsed/refractory multiple myeloma
 - <https://onlinelibrary.wiley.com/doi/full/10.1002/hem3.70114>

YouTube

- Ravi Vij & Dr. Peter Voorhees, MD | ASCO 2025: Is CARTITUDE-1 Starting to Cure Multiple Myeloma?
 - <https://www.youtube.com/watch?v=9qx7ckUWzel>
- Ravi Vij & Dr. Attaya Suvannasankha, MD Discusses About Use of MRD in Management of Multiple Myeloma
 - <https://www.youtube.com/watch?v=cQf3OtVKM3I>

HealthCare Unfiltered Podcast

- Advances in Multiple Myeloma: Report from ASCO and EHA 2025 – Dr. Ben Durman
 - <https://podcasts.apple.com/us/podcast/advances-in-multiple-myeloma-report-from-asco-and-eha-2025/id1534737585?i=1000717354446>

MEDPAGE Today

- Myeloma Drug's Comeback Nixed by FDA Panel
 - <https://www.medpagetoday.com/hematologyoncology/myeloma/116562>

Cancer Therapy Advisor

- **FDA Approves New Dosing Schedule for Elrexfio in Rel/Ref Multiple Myeloma**

- <https://www.cancertherapyadvisor.com/news/fda-approves-new-dosing-schedule-for-elrexfio-in-rel-ref-multiple-myeloma/>

Sanofi

- **Press Release: Sanofi's SAR446523, a GPRC5D monoclonal antibody, earns orphan drug designation in the US for multiple myeloma**

- <https://www.sanofi.com/en/media-room/press-releases/2025/2025-07-30-05-00-00-3123737>

Oncology Nurse Advisor

- **Many Ineligible for Clinical Trial Could Benefit From Teclistamab for Multiple Myeloma**

- <https://www.oncologynurseadvisor.com/news/many-ineligible-for-clinical-trial-could-benefit-from-teclistamab-for-multiple-myeloma/>

Dana Farber

- **Dana-Farber Cancer Institute Unveils Groundbreaking Blood Test for Multiple Myeloma**

- <https://www.dana-farber.org/newsroom/news-releases/2025/dana-farber-cancer-institute-unveils-groundbreaking-blood-test-for-multiple-myeloma>

X

- What is palliative care for multiple myeloma—and why is it so important? (Dr. Joeseeph Mikhael)
 - <https://x.com/IMFmyeloma/status/1942954475670368569>
- What does the FDA ODAC vote on the AQUILA trial mean for patients with high risk smoldering myeloma? (Dr. Joseph Mikhael)
 - <https://x.com/IMFmyeloma/status/1949243024782889082>
- Should Darzalex (daratumumab) continue after transplant alongside Revlimid (lenalidomide)? (Dr. Joseph Mikhael)
 - <https://x.com/IMFmyeloma/status/1955002334104141971>
- Frontline therapy matters...Dr. Joseph Mikhael breaks down new data from the Perseus study and why it could change how we treat newly diagnosed myeloma.
 - <https://x.com/IMFmyeloma/status/1954905765526773869>